The Prime Minister Syed Yusuf Raza Gillani directed the Cabinet Secretary to ensure uninterrupted provision of drugs and medicines to the patients all over the country and resolution of all outstanding issues of the Pharma industry. The Cabinet Secretary accordingly took appropriate measures to resolve outstanding problems in this regard. In pursuance of the directive, the 231st Meeting of Drug Registration Board was held on 1st and 2nd August, 2011 under the Chairmanship of Drugs Controller Registration.

The meeting was attended by members of the Board including experts with 20-40 years experience in the field of drug regulation, medicine, pharmacy, drug manufacturing and testing, law, intellectual property rights, veterinary sciences and the Army Medical Corps. The representatives of Provincial Health Departments, Fauji Foundation Medical College, Veterinary and Pharmaceutical Universities. Observers from stake holders i.e. Pakistan Pharmaceutical Manufacturer’s Association, Pharma Bureau, Pakistan Chemists & Druggist Association and Pakistan Veterinary Pharmaceutical Association also participated.

During two days of deliberation, the Drug Registration Board considered 2500 pending applications. The Board approved 30 medical devices and about 210 single and multiple ingredient drugs in various presentations like tablets, capsules, injections, syrups of different potencies. Products approved for registration include pharmaceuticals, biologicals, anti cancer and drugs for thallasemia treatment. The medical devices including stents used in cardiac procedures were also registered. Registrations have also been granted for certain medical devices, vaccines, sera and biological products which are either not produced in the country or their production is not adequate to meet the requirements. The products were approved for 30 newly licensed units while 42 pharmaceutical units who established 104 new sections for various dosage forms and 72 manufacturers who have made substantial improvements in their already existing facilities. Total investment in these activities is estimated to be Rs. 1.5-2.5 billions.

4. Registration Board approved 164 products for de-registration as they had become obsolete or commercially not viable for the manufacturers. 5. Drug Registration Board expects that grant of these registrations would encourage manufacturing and supply of quality pharmaceutical, biological, anti cancer, thalassemia drugs and medical devices at economical prices.

Comments

Search RSS

All rights reserved."